Back

The safety and efficacy of quadruple ultra-low-dose combination (quadpill) for hypertension treatment: a meta-analysis of randomized controlled trials

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Drugs and devices in hypertension Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Mahmoud Ibrahim

McLaren Flint Hospital, Flint (United States of America)

7 More presentations in this session

Presentation thumbnail
Efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in essential hypertension
Professor J. Wang (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Comparing cardiovascular outcomes and costs of perindopril-, enalapril- or losartan-based antihypertensive regimens in South Africa: real-world medical claims database analysis
Professor N. Ntusi (Rondebosch, ZA)
Abstract Slides Video
Presentation thumbnail
Neuroprotective efficacy of combined antihypertensive treatment with the inclusion of nitrendipine in patients with arterial hypertension
Associate Professor G. Abdullaeva (Tashkent, UZ)
Abstract Slides Video
Presentation thumbnail
Effects of blood pressure lowering according to baseline cardiovascular disease: systematic review and meta-analysis of randomized trials
Doctor E. Manta (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Improved health-related quality of life after renal denervation in patients with resistant hypertension: 3-year outcomes in the global symplicity registry
Associate Professor F. Mahfoud (Basel, CH)
Abstract Slides

Access the full session

Session thumbnail
Drugs and devices in hypertension

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
The floor is yours: bring your questions about optimal blood pressure control for organ protection - expert panel
thumbnail
Congress Presentation
Hypertension, diabetes, and the kidney: a triple threat for adverse cardiovascular events?
thumbnail
Congress Presentation
Hypertension and glucose

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources